Eli Lilly

Eli Lilly and XtalPi have entered an AI drug discovery collaboration of up to $250 million in upfront and milestone payments. XtalPi is a pharmaceutical technology company with operations in China and the US. The collaboration will use XtalPi’s integrated AI and robotics platform ID4Inno to de novo design and deliver drug candidates for an […]

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the foundation of the NHS.  As […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental […]

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been seen in the announcement of positive trial data […]

A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes.  The DINAMO Phase III clinical trial demonstrated a statistically significant reduction in HbA1c with empagliflozin compared with placebo for children and adolescents aged 10-17 years […]

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).  The approval means that abemaciclib will be able to be used in combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative, […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   Abemaciclib will now be able to be used in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human […]